Patents by Inventor Travis Mickle

Travis Mickle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170246307
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20170246308
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20170246301
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20170247368
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20170226118
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 10, 2017
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Publication number: 20170209586
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids, such as Lysine to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: February 13, 2017
    Publication date: July 27, 2017
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Patent number: 9682076
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxymorphone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxymorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: June 20, 2017
    Assignee: KEMPHARM, INC.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Jaroslaw Kanski, Andrea Martin
  • Publication number: 20170143696
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: December 12, 2016
    Publication date: May 25, 2017
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Publication number: 20170143839
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-?-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: December 30, 2016
    Publication date: May 25, 2017
    Inventors: Travis Mickle, Sven Guenther, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 9650387
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: May 16, 2017
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 9597403
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: March 21, 2017
    Assignee: KEMPHARM, INC.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20170049765
    Abstract: The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.
    Type: Application
    Filed: August 26, 2016
    Publication date: February 23, 2017
    Inventors: Sven Guenther, Guochen Chi, Bindu Bera, Travis Mickle, Sanjib Bera
  • Publication number: 20170042906
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.
    Type: Application
    Filed: November 1, 2016
    Publication date: February 16, 2017
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Patent number: 9566343
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-?-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: February 14, 2017
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 9549923
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: January 24, 2017
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 9511149
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: December 6, 2016
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Patent number: 9453037
    Abstract: The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: September 27, 2016
    Assignee: KEMPHARM, INC
    Inventors: Sven Guenther, Guochen Chi, Bindu Bera, Travis Mickle, Sanjib Bera
  • Publication number: 20160200731
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: March 21, 2016
    Publication date: July 14, 2016
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Publication number: 20160193204
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: August 4, 2015
    Publication date: July 7, 2016
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Publication number: 20160168160
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxycodone (4,5-?-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 16, 2016
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Bindu Bera, Jaroslaw Kanski, Andrea Martin